Updated November 2026
Quick answer: In the only head-to-head trial (SURMOUNT-5, published in the New England Journal of Medicine in 2025), tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy): an average 20.2% of body weight against 13.7% after 72 weeks, in adults with obesity but without diabetes. Side effects were similar and mostly digestive. Semaglutide has the longer track record and a proven reduction in heart attacks and strokes, and it comes as a daily pill as well as a weekly injection. Tirzepatide is also approved for obstructive sleep apnea. Self-pay prices are now similar: from $299 a month for tirzepatide and from $349 for semaglutide injections in late 2026, or $149 for the starting-dose semaglutide pill.
Semaglutide vs Tirzepatide at a Glance
| Semaglutide | Tirzepatide | |
|---|---|---|
| Brand names for weight loss | Wegovy (injection and tablets) | Zepbound (injection: pen or vial) |
| Brand names for type 2 diabetes | Ozempic (injection), Rybelsus (tablet) | Mounjaro (injection) |
| How it works | Mimics one gut hormone, GLP-1 | Mimics two gut hormones, GIP and GLP-1 |
| Dosing | Weekly injection (maintenance 2.4 mg; 7.2 mg high-dose pen available) or daily tablet (25 mg) | Weekly injection (maintenance 5, 10 or 15 mg) |
| Average weight loss, head-to-head (72 weeks) | 13.7% | 20.2% |
| Other FDA-approved uses (weight-loss brand) | Reducing heart attack, stroke and CV death in people with heart disease; MASH liver disease; teens 12+ | Moderate-to-severe obstructive sleep apnea with obesity |
| Most common side effects | Nausea, diarrhea, vomiting, constipation | Nausea, diarrhea, vomiting, constipation |
| Boxed warning | Thyroid C-cell tumors in rodents | Thyroid C-cell tumors in rodents |
Sources: Wegovy prescribing information (revised June 2026), Zepbound prescribing information (revised August 2026), Aronne et al., NEJM 2025.
The Head-to-Head Trial: SURMOUNT-5
- Who: 751 adults with obesity and without type 2 diabetes, randomly assigned 1:1.
- What: the highest dose each person could tolerate: tirzepatide 10 or 15 mg, or semaglutide 1.7 or 2.4 mg, once a week for 72 weeks, alongside diet and activity advice. The trial was open-label (participants knew which drug they took).
- Weight: −20.2% with tirzepatide against −13.7% with semaglutide.
- Waist: −18.4 cm (7.2 in) against −13.0 cm (5.1 in).
- More people on tirzepatide reached 10%, 15%, 20% and 25% weight loss.
- Side effects: mostly digestive, mild to moderate, mainly while the dose was being increased, in both groups.
- Caveats: the study was funded by Eli Lilly, which makes tirzepatide, and it didn't test the newer 7.2 mg semaglutide dose or the semaglutide pill.
What that means in pounds
For someone starting at 105 kg (231 lb), the average results would be a loss of about 21.2 kg (47 lb) on tirzepatide and 14.4 kg (32 lb) on semaglutide. Individual results vary widely: some people lose much more, and some lose little.
Cost in Late 2026 (Self-Pay)
| Product | Monthly self-pay price (manufacturer programs, checked November 2026) |
|---|---|
| Zepbound KwikPen or vials | From $299 (2.5 mg); $399 (5 mg); $499 (7.5 mg); $699 (10, 12.5 and 15 mg, KwikPen) |
| Wegovy injection | $349 (0.25 - 2.4 mg) after a $199 introductory offer for the first two fills through December 31, 2026; $399 for Wegovy HD 7.2 mg |
| Wegovy tablets | $149 (1.5 mg); $199 (4 mg); $299 (9 mg and 25 mg) |
| Medicare (GLP-1 Bridge, from July 1, 2026) | Eligible patients pay about $50 a month for covered products |
With commercial insurance that covers them, copay cards can bring the cost down to as little as $25 a month. Both makers say their self-pay prices will be updated after December 31, 2026, so check before you fill.
Side Effects and Safety
- Digestive effects (nausea, diarrhea, vomiting, constipation, reflux) are the most common with both. They're worst while the dose is being increased, and slower titration helps.
- Serious but less common: pancreatitis, gallbladder disease, kidney injury from dehydration, severe stomach problems, low blood sugar when combined with insulin or sulfonylureas.
- Not for people with a personal or family history of medullary thyroid cancer or MEN 2, and not during pregnancy.
- Surgery and sedation: tell your anesthesiologist, because these drugs slow stomach emptying.
- Birth control pills (tirzepatide): the Zepbound label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and after each dose increase.
Which One Should You Choose?
| If you... | Consider |
|---|---|
| Want the largest average weight loss | Tirzepatide |
| Have established heart disease and want the proven cardiovascular benefit | Semaglutide (Wegovy) |
| Prefer a pill to injections | Semaglutide tablets |
| Have obstructive sleep apnea with obesity | Tirzepatide |
| Have MASH liver disease with fibrosis | Semaglutide (Wegovy) |
| Had side effects on one | The other is a reasonable switch under your clinician's care |
Whichever you take, the weight usually comes back if you stop, so plan for long-term use or a careful transition. Pair it with enough protein and strength training to protect muscle.
Frequently Asked Questions
Which is better for weight loss, semaglutide or tirzepatide?
Tirzepatide, on average: 20.2% against 13.7% weight loss in the 72-week head-to-head SURMOUNT-5 trial.
Can you switch from semaglutide to tirzepatide?
Yes, under a prescriber's direction. People usually start tirzepatide at a dose the prescriber chooses based on tolerance, rather than continuing the old dose.
Are Ozempic and Wegovy the same drug?
Both are semaglutide. Ozempic is approved for type 2 diabetes (up to 2 mg); Wegovy is approved for weight management and heart risk reduction (2.4 mg, plus a 7.2 mg high-dose pen and tablets).
Are Mounjaro and Zepbound the same drug?
Both are tirzepatide. Mounjaro is approved for type 2 diabetes; Zepbound for weight management and obstructive sleep apnea.
Which has fewer side effects?
They were similar in SURMOUNT-5, mainly digestive and mostly during dose increases.
Is compounded semaglutide or tirzepatide the same?
No. Compounded versions aren't FDA-approved, and the shortages that allowed widespread compounding ended in 2024-2025.
Sources
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med 2025;393:26-36 (PubMed)
- Wegovy (semaglutide) prescribing information, revised June 2026
- Zepbound (tirzepatide) prescribing information, revised August 2026
- NovoCare: Wegovy self-pay pricing
- Zepbound: coverage and savings
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss
Related: compounded tirzepatide in 2026: legal status, safety and cost.
Related Guides
- Life Insurance Calculator: How Much Does Life Insurance Cost by Age?
- How Much Emergency Fund Do You Need? (With Calculator)
- Personal Finance for Beginners: A Step-by-Step Guide
- Career Guide: Work Smarter, Avoid Burnout and Grow
General health information, checked November 2026. Not medical advice: talk to your clinician about whether either drug is right for you.
0 Comments
Thanks for reading my blog,please read other topics my blog also!!!